This HTML5 document contains 105 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n15http://linked.opendata.cz/resource/drugbank/drug/DB01595/identifier/drugbank/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n23http://linked.opendata.cz/resource/AHFS/
n14http://linked.opendata.cz/resource/mesh/concept/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01595/identifier/chemspider/
n24http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n8http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n6http://linked.opendata.cz/resource/drugbank/drug/DB01595/identifier/wikipedia/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01595/identifier/pharmgkb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n20http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n13http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01595/identifier/kegg-compound/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01595/identifier/bindingdb/
n4http://linked.opendata.cz/resource/drugbank/property/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01595/identifier/pubchem-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/ontology/sukl/drug/
n19http://linked.opendata.cz/resource/atc/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01595/identifier/pubchem-substance/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01595/identifier/kegg-drug/

Statements

Subject Item
n2:DB01595
rdf:type
n3:Drug
n3:description
A benzodiazepine derivative used as an anticonvulsant and hypnotic.
n3:generalReferences
# Rickels K: The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatr Scand Suppl. 1986;332:132-41. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2883820 # Robertson MD, Drummer OH: Postmortem drug metabolism by bacteria. J Forensic Sci. 1995 May;40(3):382-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7782744 # Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines] Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2570451 # Podhorna J, Krsiak M: Behavioural effects of a benzodiazepine receptor partial agonist, Ro 19-8022, in the social conflict test in mice. Behav Pharmacol. 2000 Apr;11(2):143-51. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10877119 # Nowakowska E, Chodera A: Studies on the involvement of opioid mechanism in the locomotor effects of benzodiazepines in rats. Pharmacol Biochem Behav. 1991 Feb;38(2):265-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1676167
n3:group
approved
n3:halfLife
15-38 hours (mean elimination half life 26 hours).
n3:indication
Used to treat short-term sleeping problems (insomnia), such as difficulty falling asleep, frequent awakenings during the night, and early-morning awakening.
owl:sameAs
n8:DB01595 n24:DB01595
dcterms:title
Nitrazepam
adms:identifier
n6:Nitrazepam n9:PA10242 n10:4506 n11:C07487 n12:D00531 n15:DB01595 n16:50020856 n17:4350 n21:46505806
n3:mechanismOfAction
Nitrazepam belongs to a group of medicines called benzodiazepines. It acts on benzodiazepine receptors in the brain which are associated with the GABA receptors causing an enhanced binding of GABA (gamma amino butyric acid) to GABAA receptors. GABA is a major inhibitory neurotransmitter in the brain, involved in inducing sleepiness, muscular relaxation and control of anxiety and fits, and slows down the central nervous system. The anticonvulsant properties of nitrazepam and other benzodiazepines may be in part or entirely due to binding to voltage-dependent sodium channels rather than benzodiazepine receptors. Sustained repetitive firing seems to be limited by benzodiazepines effect of slowing recovery of sodium channels from inactivation.
n3:synonym
Relact Hipsal Mogadon Nelmat Radedorm Unisomnia Benzalin Neozepam Ro 4-5360 Pelson Atempol Hipnax Paxisyn Remnos Trazenin Sonebon Persopit Ro 5-3059 Neuchlonic 7-Nitro-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one Imeson 2,3-dihydro-7-Nitro-5-phenyl-1H-1,4-benzodiazepin-2-one Eatan Apodorm N-Desmethylnimetazepam Ibrovek Nelbon Somitran Calsmin Imesont Eunoctin Nitrazepamum Sonnolin Surem Gerson Nitrados 7-Nitro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one 1,3-dihydro-7-Nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
n3:toxicity
Nitrazepam is a drug which is very frequently involved in drug intoxication, including overdose. Nitrazepam overdose may result in stereotypical symptoms of benzodiazepine overdose including intoxication, impaired balance, slurred speech. In cases of severe overdose this may progress to a comatose state with the possibility of death.
n18:hasAHFSCode
n23:28-24-08
n3:foodInteraction
Avoid alcohol. Avoid excessive quantities of coffee or tea (Caffeine). Take with food.
n13:hasConcept
n14:M0014875
n3:IUPAC-Name
n4:271B5A17-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5A1D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5A1C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5A19-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5A1A-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5A1B-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5A15-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5A13-363D-11E5-9242-09173F13E4C5 n4:271B5A16-363D-11E5-9242-09173F13E4C5 n4:271B5A2E-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5A2F-363D-11E5-9242-09173F13E4C5 n4:271B5A14-363D-11E5-9242-09173F13E4C5
n18:hasATCCode
n19:N05CD02
n3:H-Bond-Acceptor-Count
n4:271B5A23-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5A24-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5A1E-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5A1F-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5A21-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5A20-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5A22-363D-11E5-9242-09173F13E4C5
n3:absorption
Bioavailability is 53-94% following oral administration.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
146-22-5
n3:category
n3:containedIn
n20:271B5A10-363D-11E5-9242-09173F13E4C5 n20:271B5A11-363D-11E5-9242-09173F13E4C5 n20:271B5A0E-363D-11E5-9242-09173F13E4C5 n20:271B5A0F-363D-11E5-9242-09173F13E4C5 n20:271B5A12-363D-11E5-9242-09173F13E4C5 n20:271B5A0B-363D-11E5-9242-09173F13E4C5 n20:271B5A0C-363D-11E5-9242-09173F13E4C5 n20:271B5A0D-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5A29-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5A2B-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5A2C-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5A2D-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5A28-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5A27-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5A2A-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5A18-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5A25-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5A26-363D-11E5-9242-09173F13E4C5